RT Journal Article
SR Electronic
T1 Thrombogenicity of Sirolimus-eluting Stents and Bare Metal Stents: Evaluation in the Early Phase after Stent Implantation
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 635
OP 639
VO 24
IS 5
A1 WALTER, THOMAS
A1 REY, KATJA S.
A1 WENDEL, HANS PETER
A1 SZABO, SEBASTIAN
A1 SUSELBECK, TIM
A1 DEMPFLE, CARL-ERIK
A1 BORGGREFE, MARTIN
A1 SWOBODA, STEFANIE
A1 BEYER, MARTIN E.
A1 HOFFMEISTER, HANS MARTIN
YR 2010
UL http://iv.iiarjournals.org/content/24/5/635.abstract
AB Background: Thrombogenicitiy of drug-eluting stents is a matter of controversial debate. The aim of this study was to evaluate the thrombogenicity of sirolimus-eluting stents (SES) compared to bare metal stents (BMS) in a standardised in vitro model. Materials and Methods: Nine SES and nine BMS were implanted in tubing loops and nine loops without stent served as controls. Initially and after 90 minutes of blood circulation in a modified chandler loop model, thrombin-antithrombin III complex (TAT), PMN-elastase, factor XIIa, SC5b-9, sP-selectin and platelet count were measured. Expression of CD62P, CD45/41 and PAC-1 on platelets were determined by flow cytometry. Results: After 90 minutes, platelet count decreased significantly in the loops with BMS and SES (p<0.05). Levels of TAT, PMN-elastase and SC5b-9 were significantly elevated after 90 minutes in all loops (p<0.05). sP-selectin significantly increased in the loops with BMS and SES after 90 minutes. No significant changes occurred in any flow cytometric data. Platelet count, sP-selectin, TAT, PMN-elastase, SC5b-9, CD62P, CD41/CD45 and PAC-1 showed no significant difference between BMS and SES. Conclusion: These data provide evidence that there is no difference in thrombogenicity of BMS and SES in the in vitro model.